



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

09543771

4/5/02

CARULLI

032796-014

EXAMINER

HAUSSAL

ART UNIT

PAPER NUMBER

1636

25

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) Ex. Sumesh Kaushal. (3) _____
(2) Asst. Jay E. Williams. (4) _____

Date of Interview 4/23/03

Type: Telephonic Televideo Conference Personal (copy is given to applicant applicant's representative).

Exhibit shown or demonstration conducted: Yes No If yes, brief description: see attachment

Agreement was reached. was not reached. NA

Claim(s) discussed: 1, 14-19, 26-36

Identification of prior art discussed: none

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

The applicant is considering filing an amendment that would put the instant application in a possible condition of an allowance

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has not been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

Examiner Note: You must sign this form unless it is an attachment to another form.

Sumesh
4/23/03

AGENDA FOR INTERVIEW WITH EXAMINER KAUSHAL ON APRIL 23, 2003

We plan to discuss the following:

1. possible amendments regarding the extracellular domain (*i.e.*, amino acids 23-1385) of SEQ ID NO: 4 in claims 32, 33, 35, and 36;
2. possible amendments to claim 28 to recite the "intracellular domain of the isolated amino acid sequence of SEQ ID NO: 4";
3. the rejection of claims 14-19, 26-31, 35, and 36 under 35 U.S.C. § 112, first paragraph, regarding "how to use" and "biologically active bone modulating fragments".